Last reviewed · How we verify

KIACTA (eprodisate disodium) — Competitive Intelligence Brief

KIACTA (eprodisate disodium) (KIACTA (eprodisate disodium)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amyloid inhibitor. Area: Rare Genetic Diseases / Amyloidosis.

phase 3 Amyloid inhibitor Glycosaminoglycan (GAG) synthesis and amyloid-GAG interaction Rare Genetic Diseases / Amyloidosis Small molecule Live · refreshed every 30 min

Target snapshot

KIACTA (eprodisate disodium) (KIACTA (eprodisate disodium)) — C.T. Development America, Inc.. Eprodisate disodium inhibits glycosaminoglycan (GAG) synthesis and accumulation by blocking the formation of pathogenic protein-GAG complexes in amyloid-related diseases.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
KIACTA (eprodisate disodium) TARGET KIACTA (eprodisate disodium) C.T. Development America, Inc. phase 3 Amyloid inhibitor Glycosaminoglycan (GAG) synthesis and amyloid-GAG interaction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Amyloid inhibitor class)

  1. C.T. Development America, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KIACTA (eprodisate disodium) — Competitive Intelligence Brief. https://druglandscape.com/ci/kiacta-eprodisate-disodium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: